Merck (MRK) Cash Flow Statement

Click line-items for a historical chart and %

Cash Flows from Operating Activities
Net income	8.08B
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on disposition of interest in Merial Limited	-3.16B
Gain on distribution from AstraZeneca LP	0
Equity income from affiliates	-2.5B
Dividends and distributions from equity affiliates	2.03B
Depreciation and amortization	1.66B
Deferred income taxes	2.17B
Share-based compensation	376M
Other	-514.8M
Net changes in assets and liabilities	63.4M
Net Cash Provided by Operating Activities	3.38B
Cash Flows from Investing Activities
Capital expenditures	-1.29B
Purchases of securities and other investments	-3.07B
Proceeds from sales of securities and other investments	10.71B
Acquisitions of businesses, net of cash acquired	-130M
Proceeds from sale of interest in Merial Limited	4B
Distribution from AstraZeneca LP	0
Decrease (increase) in restricted assets	5.47B
Other	33.8M
Net Cash Provided by (Used by) Investing Activities	7.94B
Cash Flows from Financing Activities
Net change in short-term borrowings	-1.09B
Proceeds from issuance of debt, net	4.23B
Payments on debt	-25.3M
Purchases of treasury stock	0
Dividends paid to stockholders	-3.22B
Proceeds from exercise of stock options	38.5M
Other	-124.3M
Net Cash Provided by (Used by) Financing Activities	-9.12B
Effect of Exchange Rate Changes on Cash and Cash Equivalents	65.4M
Net Increase in Cash and Cash Equivalents	2.26B
Cash and Cash Equivalents at Beginning of Year	4.37B
Cash and Cash Equivalents at End of Period	6.63B

Entities mentioned with MRK